OMV issues EUR 750 million perpetual hybrid notes

Alfred Stern Chairman of the Executive Board of OMV OMV
Alfred Stern Chairman of the Executive Board of OMV - OMV
0Comments

OMV Aktiengesellschaft has announced the issuance of new perpetual, subordinated hybrid notes with a total volume of EUR 750 million. The company is making strides towards its goal of becoming an integrated sustainable chemicals, fuels, and energy entity by focusing on circular economy solutions.

The securities are not intended for residents or individuals physically located in the United States, Australia, Canada, or Japan. According to the U.S. Securities Act of 1933, as amended, these securities cannot be offered or sold in the United States without registration or an exemption from registration. OMV does not plan to register this offering in the United States nor conduct a public offering there.

OMV aims to achieve net zero emissions by 2050 at the latest by gradually transitioning to low-carbon business practices. In 2024, OMV reported revenues amounting to EUR 34 billion and employed approximately 23,600 people globally. The company’s shares are listed on the Vienna Stock Exchange and also traded in the US on OTCQX.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.